Retrospective study on the efficacy of monocyte distribution width (MDW) as a screening test for COVID-19

Wakamatsu, Kentaro; Nagasawa, Zenzo; Katsuki, Kouta; Kumazoe, Hiroyuki; Yasuda, Mikio; Kawamoto, Sae; Kawamura, Ayano; Ueno, Toshihide; Kiyotani, Ruriko; Fukui, Izumi; Maki, Sanae; Nagata, Nobuhiko; Kawasaki, Masayuki; Yamada, Hozumi

doi:10.1186/s40001-023-01086-7

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MDW, which has been used as a novel biomarker for the detection of sepsis, 70 has been reported in several recent studies on COVID-19. 71,72 In our pooled results, MDW showed the superior discriminatory ability in identifying SARS-CoV-2 infection. Shahri et al identified significant differences in the function and morphology of monocytes between COVID-19 patients and healthy individuals, 73 supporting the view that MDW can help to identify COVID-19 patients.…”

Section: Discussionmentioning

confidence: 62%

“…MDW, which has been used as a novel biomarker for the detection of sepsis, 70 has been reported in several recent studies on COVID-19. 71,72 In our pooled results, MDW showed the superior discriminatory ability in identifying SARS-CoV-2 infection. 75 suggesting that MDW may be a useful tool for predicting a higher risk of adverse outcomes in COVID-19.…”

Section: Discussionmentioning

confidence: 67%

See 1 more Smart Citation

Novel inflammatory biomarkers in the prognosis of COVID-19

Zhan,

Wang,

Lin

et al. 2023

Ther Adv Respir Dis

View full text Add to dashboard Cite

Background: The central role of inflammatory progression in the development of Coronavirus disease 2019 (COVID-19), especially in severe cases, is indisputable. However, the role of some novel inflammatory biomarkers in the prognosis of COVID-19 remains controversial. Objective: To assess the effect of some novel inflammatory biomarkers in the occurrence and prognosis of COVID-19. Methods: We systematically retrieved the studies related to COVID-19 and the inflammatory biomarkers of interest. The data of each biomarker in different groups were extracted, then were categorized and pooled. The standardized mean difference was chosen as an effect size measure to compare the difference between groups. Results: A total of 90 studies with 12,059 participants were included in this study. We found higher levels of endocan, PTX3, suPAR, sRAGE, galectin-3, and monocyte distribution width (MDW) in the COVID-19 positive groups compared to the COVID-19 negative groups. No significant differences for suPAR and galectin-3 were detected between the severe group and mild/moderate group of COVID-19. In addition, the deaths usually had higher levels of PTX3, sCD14-ST, suPAR, and MDW at admission compared to the survivors. Furthermore, patients with higher levels of endocan, galectin-3, sCD14-ST, suPAR, and MDW usually developed poorer comprehensive clinical prognoses. Conclusions: In summary, this meta-analysis provides the most up-to-date and comprehensive evidence for the role of the mentioned novel inflammatory biomarkers in the prognosis of COVID-19, especially in evaluating death and other poor prognoses, with most biomarkers showing a better discriminatory ability.

show abstract

Section: Discussionmentioning

confidence: 62%

“…MDW, which has been used as a novel biomarker for the detection of sepsis, 70 has been reported in several recent studies on COVID-19. 71,72 In our pooled results, MDW showed the superior discriminatory ability in identifying SARS-CoV-2 infection. 75 suggesting that MDW may be a useful tool for predicting a higher risk of adverse outcomes in COVID-19.…”

Section: Discussionmentioning

confidence: 67%

Novel inflammatory biomarkers in the prognosis of COVID-19

Zhan,

Wang,

Lin

et al. 2023

Ther Adv Respir Dis

View full text Add to dashboard Cite

show abstract

Monocyte distribution width (MDW) and DECAF: two simple tools to determine the prognosis of severe COPD exacerbation

Amado,

Ghadban,

Manrique

et al. 2024

Intern Emerg Med

View full text Add to dashboard Cite

Monocyte distribution width (MDW) has been associated with inflammation and poor prognosis in various acute diseases. Chronic obstructive pulmonary disease (COPD) exacerbations (ECOPD) are associated with mortality. The objective of this study was to evaluate the utility of the MDW as a predictor of ECOPD prognosis. This retrospective study included patient admissions for ECOPD. Demographic, clinical and biochemical information; intensive care unit (ICU) admissions; and mortality during admission were recorded. A total of 474 admissions were included. MDW was positively correlated with the DECAF score (r = 0.184, p < 0.001) and C-reactive protein (mg/dL) (r = 0.571, p < 0.001), and positively associated with C-RP (OR 1.115 95% CI 1.076–1.155, p < 0.001), death (OR 9.831 95% CI 2.981– 32.417, p < 0.001) and ICU admission (OR 11.204 95% CI 3.173–39.562, p < 0.001). High MDW values were independent risk factors for mortality (HR 3.647, CI 95% 1.313–10.136, p = 0.013), ICU admission (HR 2.550, CI 95% 1.131–5.753, p = 0.024), or either mortality or ICU admission (HR 3.084, CI 95% 1.624–5.858, p = 0.001). In ROC analysis, a combined MDW–DECAF score had better diagnostic power (AUC 0.777 95% IC 0.708–0.845, p < 0.001) than DECAF (p = 0.023), MDW (p = 0.026) or C-RP (p = 0.002) alone. MDW is associated with ECOPD severity and predicts mortality and ICU admission with a diagnostic accuracy similar to that of DECAF and C-RP. The MDW– DECAF score has better diagnostic accuracy than MDW or DECAF alone in identifying mortality or ICU admission.

show abstract

Retrospective study on the efficacy of monocyte distribution width (MDW) as a screening test for COVID-19

Cited by 2 publications

References 23 publications

Novel inflammatory biomarkers in the prognosis of COVID-19

Novel inflammatory biomarkers in the prognosis of COVID-19

Monocyte distribution width (MDW) and DECAF: two simple tools to determine the prognosis of severe COPD exacerbation

Contact Info

Product

Resources

About